Product Images Eltrombopag

This is a product description for Itrombopag tablets, each containing 12.5 mg of elrombopag olamine. The tablets are film-coated and should be swallowed whole without splitting, chewing, or crushing. The recommended dosage and storage instructions are provided on the package insert. Safety closures should be used when dispensing the product, and the medication guide is available online. The tablets should be stored at 20° to 25°C (68° to 77°F). Contact information for the manufacturer and distributor is also included.*

This is a medication label detailing information about Itrombopag tablets, including dosage instructions, storage conditions, and safety precautions. It mentions that the tablets should be swallowed whole and not split, chewed, or crushed. The label also provides the dosage amount and the equivalent content in each tablet. It includes details on where to find the Medication Guide for further information and contact numbers in case of inquiries. It specifies the manufacturer information and the necessary precautions to keep the medication out of reach of children.*

This is a medication label providing important information about a product called Itrombopag Tablets, each containing 50 mg of the active ingredient. The tablets are intended to be swallowed whole and not split, chewed, or crushed. The label includes instructions for storage, dosage information, and details on how to access the Medication Guide for further assistance. Additionally, safety precautions are outlined, such as using safety closures and keeping the tablets out of reach of children. The manufacturer contact details are also provided for any inquiries or assistance needed.*

This is the packaging information for Itrombopag Tablets, with each film-coated tablet containing eltrombapag olamine equivalent to 75 mg of eltrombopag. It is advised to swallow the tablets whole and store them at 20° to 25°C. The medication guide is available online. The tablets should be dispensed in the original bottle, and safety closures are recommended. Contact the manufacturer Evarc Pharmaceuticals or XLCare Pharmaceutical, Inc. for any further queries or information.*